---
title: "Stryker Corp 2Q 2026: Revenue $6.59B, EPS $3.3— 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294535245.md"
description: "Stryker Corp reported Q2 2026 revenue of $6.59B and diluted EPS of $3.3, up 9.4% and 44.1% year-over-year respectively. Growth was driven by higher unit volumes in MedSurg, Neurotechnology, and Orthopaedics. Net income rose to $1.28B. Gross margin improved due to tariff reversals and reduced inventory amortization, while cost discipline supported operating margin gains."
datetime: "2026-07-31T15:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294535245.md)
  - [en](https://longbridge.com/en/news/294535245.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294535245.md)
---

# Stryker Corp 2Q 2026: Revenue $6.59B, EPS $3.3— 10-Q Summary

Stryker Corp reported second-quarter 2026 results with revenue of $6.59B and diluted EPS of $3.3, driven by higher unit volumes across MedSurg, Neurotechnology and Orthopaedics and resulting in stronger net earnings versus the year-ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$6.59B

$6.02B

9.4%

Net income²

$1.28B

$884M

44.3%

Diluted EPS³

$3.3

$2.29

44.1%

_¹ Reported as “Net sales”. ² Reported as “Net earnings”. ³ Reported as “Diluted earnings per share of common stock”._

**Business Highlights**

-   Revenue growth was broad-based with MedSurg and Neurotechnology leading the expansion; Orthopaedics and Trauma/Extremities also posted notable unit-volume gains.
-   U.S. sales rose while international revenue grew faster, with foreign exchange contributing roughly 0.4–1.1% to growth.
-   Gross margin improved due to tariff reversals and reduced inventory step-up amortization; the company continues to manage impacts from a prior cybersecurity incident that affected production in Q1.
-   Continued cost discipline, structural optimization and integration efforts supported operating margin and adjusted EPS improvements.

Original SEC Filing: STRYKER CORP \[ SYK \] - 10-Q - Jul. 31, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [SYK.US](https://longbridge.com/en/quote/SYK.US.md)

## Related News & Research

- [Stryker: Analyst Sees Share Weakness as a Chance to Buy into a Durable High-Growth Medtech Leader](https://longbridge.com/en/news/294604604.md)
- [15,653 Shares in Stryker Corporation $SYK Bought by First Nebraska Trust Co](https://longbridge.com/en/news/294600116.md)
- [Stryker Q2 adjusted EPS beats estimates, narrows 2026 outlook](https://longbridge.com/en/news/294410030.md)
- [Stryker (NYSE:SYK) Announces Quarterly Earnings Results](https://longbridge.com/en/news/294418968.md)
- [Stryker (SYK) Could Be 15% Below Fair Value As Mako RPS Launch Draws Focus](https://longbridge.com/en/news/293831896.md)